Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma

Key Points

• The aim is to evaluate the patient-reported outcomes from the nivolumab combination therapy in nasopharyngeal carcinoma while avoiding cisplatin.
• Conducted a phase 2 trial focusing on nivolumab and its effects.
• Enrolled patients diagnosed with nasopharyngeal carcinoma.
• Assessed patient-reported outcomes related to quality of life and treatment satisfaction.
• Patients reported improved quality of life compared to traditional treatments.
• Treatment was generally well tolerated without significant cisplatin-related side effects.